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Abstract
The development of a sensitive and specific detection platform for exosome is highly desirable 
as they are believed to transmit vital tumour-specific information (mRNAs, microRNAs and 
proteins) to the remote cells for secondary metastasis. Herein, we report a simple method for the 
real-time and label free detection of clinically relevant exosomes using surface plasmon 
resonance (SPR) biosensor. Our method shows high specificity in detecting BT474 breast cancer 
cell derived exosomes particularly from complex biological samples (e.g., exosome spiked in 
serum). This approach exhibits high sensitivity by detecting as low as 8280 exosomes/µL which 
may potentially be suitable for clinical analysis. We believe that this label free and real time 
method along with the high specificity and sensitivity may potentially be useful for clinical 
settings.
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1. Introduction
With a variety of vesicles secreted by eukaryotic cells, exosomes have attracted much attention 
for their ability to carry vital molecular information representative of the parent cell [1–5]. This 
discovery has spurred enormous interest in realising their potential as non-invasive disease 
markers and subsequently in the development of exosome-based diagnostic platforms [6–10]. 
However, a major bottleneck in the development of such platforms has been the specific 
isolation of exosomes from complex biological fluids. Over the years, several methods utilized 
for the isolation of exosomes including ultracentrifugation [11], density gradient separation 
followed by electron microscopy [12], enzyme-linked immunosorbent assays (ELISA) [13], and 
western blotting [14] resulted in low purity yield, tend to be time consuming or involve extensive 
labelling procedures [15]. Similarly, several commercially available exosome isolation protocols 
or kits also co-isolate several non-exosome debris or biological material of similar physical 
characteristic rendering them to be ineffective. 
Recent integration of microfluidics [16–18], immunosensors [19–23], and plasmonic sensors 
[24–29] has enabled the development of promising point-of-care devices for disease detection. 
These technology enhancements have significantly improved the capability of isolating exosome 
populations in a sensitive manner. For instance, a nano-plasmonic assay developed by Im et al. 
enabled profiling of exosomes based on membrane proteins and proteins present in the lysates 
[24]. The approach involved the use of periodically placed antibody-functionalized nanohole 
arrays and exosome profiling was performed by using transmission surface Plasmon resonance 
system. To avoid the nanostructure fabrication complexity for nano-plasmonic sensor 
development, Liu et al developed a compact SPR biosensor for exosomal protein detection [30]. 
The assay involved conventional SPR biosensing mechanism but does not require a 
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nanostructure fabrication. Similarly, Picciolini et. al. reported a Surface Plasmon Resonance 
imaging assay that detected exosome subpopulations in blood derived from neurons and 
oligodendrocytes and demonstrated the heterogeneity in EV populations in terms of phenotypic 
expression and abundance [31]. Rupert et al recently developed another Surface Plasmon 
Resonance based method that utilised dual wavelengths to accurately measure the size and 
concentrations of exosome subpopulations [32]. Apart from the SPR based methods, 
Duraichelvan et al reported a label free method based on UV-VIS spectrophotometer that utilizes 
an exosome capturing synthetic polypeptide to detect exosomes in liquid biopsy [33]. A high 
performance microfluidic platform was developed by Shao et al. and colleagues which utilized 
magnetic particle tagged antibody to detect exosomes isolated using a nuclear magnetic 
resonance system [34]. In addition to these, numerous other microfluidic approaches based on 
microfabricated electric field-induced fluid micromixing, constricted nanochannels to induce 
cell-mediated exosome release, micropillars or geometric features sequentially arranged with 
lateral displacement have been utilised for the successful isolation of exosomes using exosomal 
membrane based cancer biomarkers [15–18, 35]. Although these techniques are highly sensitive, 
time consuming procedure and expensive instrumentation limits their applicability in clinical 
settings. More recently, we have developed a surface plasmon resonance (SPR) based method 
that can enumerate the proportion of tumour derived exosomes within the bulk exosome 
population isolated from patient serum. The method required a sandwich assay where bulk 
exosome population (both normal and tumour derived exosome) were initially captured in the 
sensor surface domain using a generic marker (e.g. CD63 or CD69) and then used to detect the 
tumour specific exosomes using a secondary detection antibody such as HER2. Since this 
method used a sandwich assay with secondary detection antibody, it required long analysis time. 
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Thus we believe that a simple and direct assay without a labelling with secondary detection 
antibody might have potential application in point of care diagnostics.  
Herein, we report a simple approach for the specific and sensitive detection of clinically relevant 
exosomes from biological fluids. Our proof of concept study involves a simple custom-built 
surface plasmon resonance (SPR) readout system that enables a rapid, real-time and label-free 
monitoring of exosomes without relying on labelling with a secondary antibody. While the 
removal of the secondary antibody label resulted in a reduction in assay time and the use of 
custom built SPR reduce the system cost. We successfully demonstrate the ability of our method 
to detect human epidermal growth factor receptor 2 (HER2) specific exosomes derived from 
BT474 breast cancer cell line. Our approach exhibits high sensitivity by detecting as low as 8280 
exosomes/µL from complex biological samples (e.g., exosome spiked in serum) which is 
potentially suitable for clinical analysis. We believe that this simple method may potentially 
enable its integration as a clinical or point-of-care testing tool [36].
2. Materials and Methods
2.1 Chemicals and reagents
Analytical grade chemical reagents were purchased from Sigma Aldrich (Australia).  
UltraPure™ DNase/RNase-free distilled water (Invitrogen, Australia) were used to carry out all 
the experiments. Reagents for immunoassay were purchased from R&D/Life Technologies 
(Burlington, ON), Thermo-Fisher Scientific (Australia), Abcam (Australia) and Invitrogen 
(Australia). Phosphate buffer saline (PBS, 10 mM, pH 7.4) was used to prepare all reagents and 
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washing solutions.  Breast cancer cells lines such as BT474 and MDA-MB-231 were purchased 
from ATCC (USA).
2.2 Cell culture and isolation of exosomes
Breast cancer (HER2 (+): BT-474; HER2 (-): MDA-MB-231) and prostate cancer (PSA (+): 
PC3) cell lines are maintained in micro-vesicles depleted serum free Media 171 (Gibco, UK) 
supplemented with mammary epithelial supplement (Gibco, UK), 1% Pencillin/streptomycin. 
The cells were grown in 5% CO2 at 37ºC and after 60 h, the cell culture medium from 106 cells 
were collected for exosome isolation. The cell debris and other contaminations were eliminated 
by centrifuging at 2000×g for 30 min. Total Exosome Isolation kit (Life Technologies) were 
used to isolate exosomes as per manufacturer’s instructions. Briefly, the isolation reagent was 
added in a ratio of 1:2 to the cell culture supernatant. The samples were then incubated for 
overnight at 4ºC and exosome pellets were obtained by filtrating the solution using 0.22 μm filter 
followed by centrifugation at 10000 × g for 1h. Isolated exosome pellets were re-suspended in 
100 μL PBS (10 mM, pH 7.0) and stored at -20ºC for future use. 
2.3 Cryo-transmission electron microscopy (Cryo-TEM)
Prepared Exosome samples (4 μL) were adsorbed on lacey carbon grids (Quantifoil, Germany) 
and then by using an FEI Vitrobot Mark 3 (FEI Company, The Netherlands), plunged into liquid 
ethane. Grids were blotted at 100% humidity at 4 ºC for about 3-4s. Frozen/vitrified samples 
were imaged using Tecnai T12 Transmission Electron Microscope (FEI Company) operating at 
an acceleration voltage of 120 kV. Images were taken at 30,000x magnification, (approximate 
dose of 13.6 electrons/Å2), using an FEI Eagle 4k CCD (FEI Company), and Serial EM image 
acquisition software.
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2.4 Device functionalization
The experiments were carried out in a custom-made SPR platform (Electronic Supplementary 
Information Figure S1) that was controlled and the signals monitored by LabVIEW Software 
(National Instruments Pty Ltd, Australia). The fabrication of the SPR sensor chips was by the 
deposition of 5 nm Ti and 50 nm Au on a 4-inch boroflat glass wafer using a Temescal BJD-
2000 e-beam evaporator. The gold-deposited wafer was then diced into the SPR sensor chips 
followed by washing of the chips in acetone, ethanol, and purified water. Next, the chips were 
dipped quickly (2-3 s) into piranha solution (70% H2SO4–30% H2O2), rinsed with water and 
dried with a stream of nitrogen gas. Finally, the chip was inserted into the SPR platform and 
conditioned with PBS buffer at a flow rate of 0.6 mL/h.  To functionalise the chips, 250 μL of 
biotinylated BSA (100 μg/mL in PBS, Invitrogen) were flown through the platform at 0.6 mL/h 
prior to the blocking of the gold surface with 3% BSA. Next, 100 μg/mL streptavidin 
(Invitrogen) was conjugated to the biotinylated BSA gold surface. The chip functionalization 
was completed by incubation with 10 µg/mL biotinylated anti-HER2 antibody.
2.5 Exosome capture and detection
Tunable resistive pulse sensing using qNano (iZON Science, New Zealand) was used to 
determine the concentration of exosomes as described previously [37]. The concentrations were 
measured by calibrating particle count rate against a reference particle (polystyrene beads, d = 
115 nm) suspension. Exosome samples were then prepared by spiking exosomes in PBS (1 mM, 
pH 7.0, 250µL) or undiluted human serum (250µL) to obtain desired concentrations 
(3.31x104exosomes/µL, 1.66x104 exosomes/µL, 1.10x104exosomes/µL and 0.828x104 
exosomes/µL,). Serum samples of healthy individuals were obtained from Ventyx Wesley 
Research Institute Tissue Bank, Brisbane, Australia under the UQ HREC ethical approval 
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number 2011001315 and Bellberry application number 2015-12-817. The serum samples were 
stored in −80°C until further use. The target samples containing HER2 (+) exosomes were finally 
captured by passing through the previously functionalised SPR chip using SPR system.
3. Results and Discussion
3.1 Assay principle
Fig. 1 represents the methodological approach for the isolation and detection of tumour specific 
exosomes from biological samples. The SPR chips were functionalised using standard biotin-
avidin chemistry to harbour an antibody targeting tumour-derived exosomes. We utilise this 
approach to demonstrate the specific capture and detection of tumour-derived exosomes 
expressing human epidermal growth factor receptor 2 (HER2) which is a potential breast cancer 
biomarker. In a typical assay, biological samples containing target HER2(+) exosomes were 
driven through the SPR chip, with exosome isolation being monitored in real-time from the 
resulting SPR spectral shift.
3.2 Isolation and characterization of exosomes from cancer cell line 
To investigate the potential of our approach in capturing exosomes, we initially obtained 
populations of breast cancer cell line (e.g. BT474) derived exosomes that potentially over 
express HER2 biomarker [38]. Next, we characterized the isolated exosomes using cryo-
transmission electron microscopy (TEM). cyro-TEM analysis verified the presence of nano-sized 
(50-200 nm) vesicles in the sample and suggested that these vesicles contain double-walled lipid 
membrane layers (Fig. 2a). These observations are in agreement with previous demonstrations on 
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characterization of these nano-sized vesicles, thereby suggesting these to be of exosomal origin 
[39, 40]. We then utilised these exosome populations for further experiments on the SPR chip.
3.3 Specificity of detection
Prior to validating the capture performance it is important to determine the specificity and 
accuracy of capture. In this regard, spiked samples containing 1.66x104 exosomes/µL of BT474 
derived exosomes in PBS (10 mM, pH 7.0) were driven through SPR chips functionalised using 
anti-HER2 antibody. Control experiments to validate the specificity were performed using SPR 
chips (i) without any capture antibody, (ii) functionalized with non-cognate PSA antibody, and 
(iii) functionalized with anti-HER2 and tested with spiked samples containing HER2(-) MDA-
MB-231 cell derived exosomes. Fig. 2b represents the SPR sensograms for capture and control 
experiments (replicate SPR sensograms are provided in supplementary information Fig. S3). The 
SPR signal (i.e., spectral shift = 0.4 nm) obtained for capture experiments (Fig. 2b; blue) suggest 
that our method is capable of detecting HER2 specific exosomes from the samples spiked in 
PBS. Further, the negligible SPR signals obtained for each of the control experiments (Fig. 2b; 
magenta, green and red) suggest that our approach is highly specific and can potentially be 
utilised for the analysis of exosomes from biological samples.
3.4 Sensitivity of detection
It has been previously determined that the average number of exosomes in biological sample is 
in the range from 1.0 x 105 to 3.0 x 109 exosome/µL [40, 41]. Thus, it is important that any 
approach developed for exosomes is sensitive and specific to detect exosome populations in this 
desired range. To this end, we determined the sensitivity and dynamic range of detection of our 
approach by spiking BT474 derived exosomes in desired concentrations (3.31x104 exosomes/µL, 
1.66x104 exosomes/µL, 1.10x104 exosomes/µL and 0.828x104 exosomes/µL,) in PBS and tested 
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these samples by driving them through an anti-HER2 functionalized SPR chip. The SPR signals 
were measured at 2750s as the dissociation signals were constant after 2750s. The SPR data in 
Fig. 3a clearly indicates that the assay is capable of detecting as low as 0.828x104 exosomes/µL 
in PBS. The linear dynamic range for the detection of exosomes was found to be 0.828x104 to 
3.31x104exosomes/µL (Fig. 3a and S2). This level of detection is comparable with existing 
exosome detection techniques based on microfluidics and plasmonic biosensors. More 
importantly, our approach demonstrates the detection of exosomes well within the clinically 
relevant range of exosomes, thereby indicating that our approach may potentially be applicable 
to detect tumour-derived exosomes from biological samples.
3.5 Detection of exosomes spiked in serum
Finally we tested the ability of our assay to detect tumour specific exosomes spiked in serum 
sample. Since serum is a complex matrix containing a large number of biomolecules, including 
exosomes from most viable body cells, we initially performed a negative control study by 
driving serum samples without any target exosomes through an anti-HER2 functionalized SPR 
chip and determined the background response. This resulted in an increase in SPR signal (i.e., 
SPR spectral shift = 4.83 nm shown in SPR sensogram and in the bar graph) due to the 
nonspecific adsorption and this was considered as the background noise for exosome capture 
experiment.  Designated proportion of exosomes were then spiked in serum samples to get 
desired concentrations (3.31x104exosomes/µL, 1.66x104 exosomes/µL, 1.10x104exosomes/µL 
and 0.828x104 exosomes/µL,) and driven through the anti-HER2 functionalized SPR chip. The 
SPR signals were measured at 2750s as the dissociation signals were constant after 2750s. 
However, since serum is a complex sample, the dissociation signals for the serum samples were 
monitored for longer time. The data presented in Fig. 4 shows the sensor response to detect 
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exosomes spiked in serum samples. The SPR signal increased proportionally with the increased 
number of exosomes spiked in serum samples. These data corroborate our previous experiments 
with exosome samples spiked in PBS and showed that our capture was uncompromised despite 
the complexity of the sample evident from the detection of as low as 0.828x104 exosomes/µL in 
serum samples. The capture performance of our approach is comparable with existing 
microfluidic technologies, conventional exosomes isolation methods and methods utilising nano-
plasmonic sensors [13–18]. However, the sensitivity could be further be improved using plain 
silver [42] or gold-silver-gold trilayer [43]metallic SPR chip instead of plain gold chip. The 
sensitivity and specificity of the method could also be improved by integrating alternating 
current electrohydrodynamic fluid flow and micro-mixing instead of conventional fluid pump. 
The existing methods involving nanoplasmonic sensors [24] and Surface Plasmon Resonance 
imaging (SPRi) [25] demonstrate remarkable capture performances and also facilitate specific 
isolation of exosomes from clinical samples. However, nanostructure fabrication for 
nanoplasmonic sensors and expensive setup for SPRi restricted their integration into the clinical 
settings. In contrast, the alternative proof-of-concept approach presented here involves a simple 
custom-built readout system that enables a rapid, real-time and label-free monitoring of exosome 
capture and offers potential as a simple diagnostic tool. We believe further improvements to the 
assay parameters, experimental protocol and potential advancement towards a custom-built 
multiplexed detection platform could improve the applicability of our approach in clinical 
system.
4. Conclusion
We have developed a label-free and real-time technique for the detection of tumour derived 
exosomes using SPR biosensor. As compared to the conventional method, this method allows 
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highly specific, sensitive and rapid detection towards detecting exosomes. Using this proof-of-
concept method, we quantified as low as 8280 exosomes/µL in PBS which is quite comparable 
with existing conventional techniques and immuno-affinity based approaches. In addition, we 
also demonstrate the potential of our approach to identify tumour derived exosomes form 
complex biological fluid (i.e., serum) thereby remarking its potential for non-invasive 
diagnostics. However, this platform is still limited by the nonspecific adsorption of biomolecules 
to the sensor surface which could possibly be obviated by using efficient surface blocking. This 
can also be improved by introducing alternating current electro-hydrodynamic micro-mixing of 
the biomolecules which can increase antigen-antibody interaction and simultaneously shear off 
the loosely bound biomolecules from the sensor surface. We believe that this simple and low-
cost method with further improvements may potentially find numerous applications in cancer 
diagnostics.  
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Figure captions
Fig. 1. Schematic representation of the detection of tumour cell derived exosomes by SPR 
biosensor. The chip was first functionalised with biotinylated anti-HER2 (violet) using biotin-
avidin chemistry. The target samples were run through the SPR chips and the BT474 breast 
cancer cell derived exosomes were detected in real-time by the functionalized anti-HER2.
Fig. 2. Characterization and capture specificity of the cell derived exosomes. (a) Cryo-TEM 
image of the BT474 cell derived exosomes. (b) SPR signals showing spectral shift generated by 
the BT474 cell derived exosomes (1.66104 exosomes/µL spiked in PBS) driven through the 
SPR chip functionalized with anti-HER2 (blue), without anti-HER2 (magenta), with nonspecific 
anti-PSA (Green), SPR signal for the MDA-MB-231 cell derives exosomes (1.66104 
exosomes/µL spiked in PBS) run through the anti-HER2 functionalized SPR chip (red).
Fig. 3. Assay sensitivity and linearity. a) SPR signal showing spectral shift generated by the 
designated concentration of BT474 cell derived exosomes (3.31x104 exosomes/µL (red), 
1.66x104 exosomes/µL (blue), 1.10x104 exosomes/µL (green), 0.828x104 exosomes/µL (black)) 
spiked in PBS. b) Bar graphs showing the mean SPR spectral shift values for each of the 
concentrations. Each data represents the average of three separate trials (n = 3). Error bars 
represent the standard deviation of measurements (relative standard deviation (%RSD) was 
found to be <5% for n = 3).
Fig. 4. (a) SPR signal showing spectral shift generated during the capture of exosomes spiked in 
serum samples in different proportions 3.31104 exosomes/µL (black), 1.66104 exosomes/µL 
(green), 1.10104 exosomes/µL (pink), 0.828104 exosomes/µL (blue), and serum without 
exosome (red). (b) Bar graphs showing the mean SPR spectral shift values for each of the 
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concentrations. Each data represents the average of three separate trials (n = 3). Error bars 
represent the standard deviation of measurements (relative standard deviation (%RSD) was 
found to be <5% for n = 3).
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Figure 1. Schematic representation of the detection of tumour cell derived exosomes by SPR biosensor. The 
chip was first functionalised with biotinylated anti-HER2 (violet) using biotin-avidin chemistry. The target 
samples were run through the SPR chips and the BT474 breast cancer cell derived exosomes were detected 
in real-time by the functionalized anti-HER2. 
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Figure 2. Characterization and capture specificity of the cell derived exosomes. (a) Cryo-TEM image of the 
BT474 cell derived exosomes. (b) SPR signals showing spectral shift generated by the BT474 cell derived 
exosomes (1.66104 exosomes/µl spiked in PBS) driven through the SPR chip functionalized with anti-HER2 
(blue), without anti-HER2 (magenta), with nonspecific anti-PSA (Green), SPR signal for the MDA-MB-231 cell 
derives exosomes (1.66104 exosomes/µl spiked in PBS) run through the anti-HER2 functionalized SPR 
chip (red). 
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Figure 3. Assay sensitivity and linearity. a) SPR signal showing spectral shift generated by the designated 
concentration of BT474 cell derived exosomes (3.31x104 exosomes/µl (red), 1.66x104 exosomes/µl (blue), 
1.10x104 exosomes/µl (green), 0.828x104 exosomes/µl (black)) spiked in PBS. b) Bar graphs showing the 
mean SPR spectral shift values for each of the concentrations. Each data represents the average of three 
separate trials (n = 3). Error bars represent the standard deviation of measurements (relative standard 
deviation (%RSD) was found to be <5% for n = 3). 
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Fig. 4. (a) SPR signal showing spectral shift generated during the capture of exosomes spiked in serum 
samples in different proportions 3.31104 exosomes/µL (black), 1.66104 exosomes/µL (green), 
1.10104 exosomes/µL (pink), 0.828104 exosomes/µL (blue), and serum without exosome (red). (b) Bar 
graphs showing the mean SPR spectral shift values for each of the concentrations. Each data represents the 
average of three separate trials (n = 3). Error bars represent the standard deviation of measurements 
(relative standard deviation (%RSD) was found to be <5% for n = 3). 
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Description of the SPR device
We employed a custom built SPR sensor of reduced size with a single microfluidic channel 
and using wavelength interrogation at a fixed 68º angle of incidence (Figure S1). Halogen 
light source (Oceans Optics, HL-2000-HP) was fiber-coupled to a multi-mode fiber with a 
small core (Thorlabs, ɸf = 50 m, M14L01) to decrease the size of the resulting light spot. 
Light was subsequently collimated with a collimation lens (Thorlabs, C330TME-B) mounted 
inside a lens tube which also consisted of a platform that allows for tilt-correction. Finally, 
the collimated light beam was TM polarized with a UV-VIS polarizer (Thorlabs, LPVIS050). 
The reflected light was collected by a fiber-coupled (Thorlabs, f = 1 mm, M35L01) light. 
Fig. S1. Image of the SPR biosensor employed in this study and its components.
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Fig. S2.Calibration plot for the capture of exosomes spiked in PBS in different proportions 
0.83x104 exosomes/µl, 1.10x104 exosomes/µl, 1.66x104 exosomes/µl, 3.31x104 exosomes/µl 
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For Peer ReviewFig. S3. SPR signals with three replicates (from left to right) showing spectral shift generated by the 
(a) BT474 cell derived exosomes (1.66104 exosomes/µl spiked in PBS) driven through the SPR chip 
functionalized with anti-HER2, (b) without anti-HER2, (c) with nonspecific anti-PSA, (d) SPR signal for 
the MDA-MB-231 cell derives exosomes (1.66104 exosomes/µl spiked in PBS) run through the anti-
HER2 functionalized SPR chip.
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